PubMed:30843003 / 0-349 JSONTXT

{"project":"PubMed_ArguminSci","denotations":[{"id":"T1","span":{"begin":115,"end":183},"obj":"DRI_Background"}],"text":"More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.\nProstate cancer (PCa) is the most common solid cancer affecting men worldwide. Serum prostate-specific antigen (PSA) is at present the most commonly used biomarker for PCa screening, as well as a reliable marker of disease recurrence after init"}

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T2","span":{"begin":105,"end":183},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":104},"obj":"Sentence"},{"id":"T2","span":{"begin":105,"end":183},"obj":"Sentence"}],"text":"More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.\nProstate cancer (PCa) is the most common solid cancer affecting men worldwide. Serum prostate-specific antigen (PSA) is at present the most commonly used biomarker for PCa screening, as well as a reliable marker of disease recurrence after init"}